[{"countryName":"Worldwide","languageLinks":[{"languageName":"English","languageUrl":"/en.html"}]},{"countryName":"USA","languageLinks":[{"languageName":"English","languageUrl":"/en-us.html"}]},{"countryName":"Japan","languageLinks":[{"languageName":"Japanese","languageUrl":"/jp/ja.html"}]}]
The link you have selected will take you outside of the Roche Sequencing USA website.
AVENIO Surveillance and Monitoring Kits
Overview
The AVENIO Surveillance and Monitoring Kits are a portfolio of NGS assays for longitudinal monitoring of tumor burden and minimal residual disease (MRD) assessment to be used in oncology research.
Key advantages of AVENIO Surveillance and Monitoring Kits
- Purpose-built for ultra-low detection of ctDNA positive or ctDNA negative
- Smart panel design contains 180 algorithmically-defined biomarkers for longitudinal monitoring of tumor burden
- All four mutation classes (SNVs, indels, fusions and CNVs) in a single DNA workflow with exceptional sensitivity and specificity1
- Matched ctDNA (liquid biopsy) and tissue panels (same genes, gene regions and hybrid-capture workflow) to facilitate concordance analysis, tumor-informed MRD detection, or longitudinal monitoring (tissue or blood plasma to establish baseline, and blood plasma for serial testing)
- A streamlined, end-to-end workflow from extraction to analysis and reporting in 5 days
- Includes sample preparation reagents, intuitive analysis and reporting to facilitate in-house adoption of high-performance NGS assays for oncology research
Surveillance and monitoring kits
AVENIO Tumor Tissue
Surveillance Kit
A 197 gene (198kb) assay, containing 17 NCCN guideline-aligned genes, plus 471 frequently mutated disease-associated regions across 197 genes; optimized for longitudinal monitoring of tumor burden in lung and colorectal cancer.
AVENIO ctDNA
Surveillance Kit
A 197 gene (198kb) assay, containing 17 NCCN guideline-aligned genes, plus 471 frequently mutated disease-associated regions across 197 genes; optimized for longitudinal monitoring of tumor burden in lung and colorectal cancer.
- Data on file.